Abatacept: A T-Cell Co-Stimulation Modulator for the Treatment of Rheumatoid Arthritis

Clinical Rheumatology - United Kingdom
doi 10.1007/s10067-008-0964-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Abatacept: The Evidence for Its Place in the Treatment of Rheumatoid Arthritis

Core Evidence
MedicineReviewsReferencesPharmacology
2007English

CTLA4-Ig (Abatacept) Therapy Modulates T Cell Effector Functions in Autoantibody-Positive Rheumatoid Arthritis Patients

BMC Immunology
Immunology
2013English

The Efficacy and Safety of Abatacept in Rheumatoid Arthritis

Therapeutic Advances in Musculoskeletal Disease
RheumatologyOrthopedicsSports Medicine
2010English

Experience With Subcutaneous Abatacept for Rheumatoid Arthritis: An Update for Clinicians

Therapeutic Advances in Musculoskeletal Disease
RheumatologyOrthopedicsSports Medicine
2014English

T-Cell Aging in Rheumatoid Arthritis

Current Opinion in Rheumatology
Rheumatology
2014English

A Critical Evaluation of the Role of Subcutaneous Abatacept in the Treatment of Rheumatoid Arthritis: Patient Considerations

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2014English

PMS12 a Budget Impact Model for the Use of Abatacept as a First Biologic Treatment for Rheumatoid Arthritis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

T Cell Co-Stimulation: Inhibition of Immunosuppression?

Frontiers in Immunology
AllergyImmunology
2018English

Effects of Abatacept on Monocytes in Patients With Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy